Register here
Christian Klingbeil
Partner, Deal Advisory - Valuation
KPMG AG Wirtschaftsprüfungsgesellschaft
+49 89 9282 1284 Christian
Klingbeil
Phone number
Current Issue:
The new edition of our newsletter on transactions in the global life sciences industry glances back at the significant deals that took place in Q1-Q3 2024 and provides further insights on the industry’s market trends.
- In comparison to the same period last year, the life sciences sector observed a moderate decline in M&A activity which can be attributed to factors such as investors assimilating previous deals and the impact of macroeconomic conditions.
- Although there were a few notable mega deals, there was a strong preference among investors for small–mid size assets. Competitive bidding among M&A processes was less common, leading to limited price appreciation for deals.
- Notably, the industry observed investors gravitating towards private biotech companies, driven by the availability of later-stage assets that can help bolster depleting pipelines and offered favorable pricing.
- Certain drug classes, such as antibody drug-conjugates, protein degradation therapeutics, and radiopharmaceutical assets, attracted substantial attention from acquirers due to their potential for exponential growth.
- Despite economic uncertainty, the life sciences sector is expected to maintain a strong dealmaking environment due to the significant number of novel therapeutic approvals.
